Pharmacology of Respiratory Failure and Mechanical Ventilation Support

The Berlin definition categorizes acute respiratory distress syndrome by severity based on the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, measured with at least 5 cmH2O of positive end-expiratory pressure. Mild acute respiratory distress syndrome is a ratio of 201 to 300 mmHg; moderate is 101 to 200 mmHg; and severe is 100 mmHg or below. The bilateral chest imaging infiltrates must not be fully explained by effusions, lobar collapse, or nodules, and respiratory failure must not be primarily attributable to cardiac failure or fluid overload. Onset must occur within one week of a known clinical insult. Severity stratifies the risk of death and the threshold for escalating pharmacological and non-pharmacological interventions including neuromuscular blockade and prone positioning.

The pathological substrate is diffuse alveolar damage, characterized by flooding of alveoli with protein-rich edema fluid from damaged alveolar-capillary membranes, formation of hyaline membranes from fibrin and plasma proteins, loss of surfactant function producing alveolar collapse and reduced compliance, and recruitment of neutrophils whose proteases, reactive oxygen species, and inflammatory cytokines perpetuate the injury. The resulting lung is heterogeneous: some alveoli are flooded and collapsed, some are recruitable, and some remain aerated. Tidal volumes sized for the full lung weight preferentially overdistend the still-aerated regions — compounding injury through a mechanism called volutrauma, while repetitive opening and closing of recruitable regions produces atelectrauma.

The ARDSNet trial established that tidal volume limitation to 6 milliliters per kilogram of predicted body weight, with plateau pressures kept below 30 cmH2O, reduces mortality by approximately 22% compared with traditional tidal volumes of 12 milliliters per kilogram. This lung-protective ventilation strategy is now the standard of care for acute respiratory distress syndrome. Although it is primarily a ventilator management decision rather than a pharmacological one, second-year students are expected to know the tidal volume target and its rationale as USMLE Step 1 content.

The DEXA-ARDS trial demonstrated that early dexamethasone (20 mg intravenously daily for 5 days, then 10 mg daily for 5 days) reduced the number of ventilator-free days and 60-day mortality in patients with moderate-to-severe acute respiratory distress syndrome. The mechanistic rationale is that the sustained cytokine storm driving diffuse alveolar damage is glucocorticoid-sensitive in a meaningful proportion of patients, and early anti-inflammatory intervention can attenuate the inflammatory phase before irreversible fibroproliferation occurs. Dexamethasone is the preferred glucocorticoid in this setting due to its favorable potency, duration of action, and absence of mineralocorticoid activity. The timing matters — late corticosteroid administration (after 14 days) in the fibroproliferative phase has not shown consistent benefit and may be harmful.

Cisatracurium is the neuromuscular blocking agent of choice in acute respiratory distress syndrome. It is an intermediate-duration nondepolarizing agent that undergoes Hofmann elimination — spontaneous non-enzymatic degradation at physiological temperature and pH, independent of hepatic or renal function. This property makes cisatracurium uniquely suitable for critically ill patients with multi-organ dysfunction, in whom liver and kidney failure would prolong the duration of action of renally or hepatically cleared agents. The ACURASYS trial suggested that 48 hours of early neuromuscular blockade with cisatracurium improved 90-day mortality in moderate-to-severe acute respiratory distress syndrome; however, the subsequent ROSE trial, which used deeper background sedation in the control group, did not replicate this mortality benefit. Current practice reserves neuromuscular blockade for patients with life-threatening hypoxemia or severe ventilator dyssynchrony refractory to optimized sedation.

ICU-acquired weakness is the most clinically significant adverse consequence of prolonged neuromuscular blockade in critically ill patients. It manifests as generalized flaccid weakness that may persist for weeks to months after intensive care unit discharge and is associated with prolonged mechanical ventilation, delayed rehabilitation, and increased long-term mortality. The mechanism involves denervation-like changes in muscle, loss of thick (myosin) filaments, and mitochondrial dysfunction. Minimizing the duration of neuromuscular blockade and daily assessment of the need for continued blockade via train-of-four monitoring (targeting 1 to 2 twitches of 4 to minimize residual block while preventing overdose) are the principal preventive strategies.

Rocuronium is a rapid-onset nondepolarizing agent used in rapid sequence intubation and for shorter-term intensive care unit paralysis. Its primary clinical advantage is its reversibility with sugammadex — a modified gamma-cyclodextrin that encapsulates rocuronium (and vecuronium) molecules in a 1:1 complex, rapidly removing them from the neuromuscular junction and reversing paralysis within minutes regardless of depth of block. Sugammadex has largely replaced neostigmine/glycopyrrolate for reversal of rocuronium and vecuronium because it works at any depth of block, not just in the presence of spontaneous recovery, and has no cholinergic adverse effects.

Laryngeal edema from prolonged endotracheal intubation can cause post-extubation stridor and upper airway obstruction requiring reintubation. A cuff leak test — deflating the endotracheal tube cuff to assess whether air bypasses the tube, indicating adequate subglottic space — is used to identify patients at high risk for post-extubation stridor. Prophylactic methylprednisolone or dexamethasone, administered intravenously in the hours before planned extubation in patients who fail the cuff leak test, reduces the incidence of post-extubation stridor and reintubation by reducing laryngeal mucosal inflammation and edema. This is one of the few context-specific pharmacological interventions with clear benefit in the weaning phase.

Caffeine, a methylxanthine chemically related to theophylline, is the drug of choice for apnea of prematurity in neonates. It stimulates the respiratory center through adenosine receptor antagonism, increasing the drive to breathe and reducing apneic episodes. The CAP trial demonstrated that caffeine therapy for apnea of prematurity not only reduces apnea but also accelerates successful extubation and reduces the rate of bronchopulmonary dysplasia and patent ductus arteriosus — outcomes with long-term significance. Caffeine has a far more favorable safety profile than theophylline in this setting due to its wider therapeutic window. In adult intensive care unit practice, methylxanthines are occasionally used to stimulate respiratory drive in patients with central hypoventilation or severe chronic obstructive pulmonary disease with hypercapnia who are difficult to wean, though the evidence base is weaker than in neonatal practice.